Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ramu Mangena"'
Autor:
Thijn R. Brummelkamp, Bianca V. Gapp, Daniel H. Lackner, Ramu Mangena, Tom Henley, Paloma M. Guzzardo, Sebastian M.B. Nijman, Sarah Oberndorfer, Carina Banning, Alexia Carré, Tilmann Bürckstümmer
Publikováno v:
Nature Communications
Genome engineering has been greatly enhanced by the availability of Cas9 endonuclease that can be targeted to almost any genomic locus using so called guide RNAs (gRNAs). However, the introduction of foreign DNA sequences to tag an endogenous gene is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e72bd70384047624ed59f3d1714756
https://pubmed.ncbi.nlm.nih.gov/26674669
https://pubmed.ncbi.nlm.nih.gov/26674669
Autor:
Rachel Leah, Ruth Feltell, Christopher Torrance, Ramu Mangena, Annette S. Little, D P Gitterman, Holly Astley, Kyla Grimshaw, David Hughes, Jessica Hunt
Publikováno v:
Molecular Cancer Therapeutics. 12:A148-A148
Successful drug development in oncology requires a deeper understanding of the functional consequences of the diverse genetic changes observed in human cancers. For example, responses to epidermal growth factor receptor (EGFR) inhibitors are observed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cdab0794c09854ac6bfbada82dead25
https://doi.org/10.1158/1535-7163.targ-13-a148
https://doi.org/10.1158/1535-7163.targ-13-a148
Autor:
Aaron Cranston, Jim Carmichael, Christine M. Chresta, Louise Unwin, Louise J. Jones, Charlotte Knights, Niall M. B. Martin, Mark J. O'Connor, Tim Avis, Aisling O'Shaughnessy, Lucy Riches, Victoria Dunham, Ramu Mangena, Alan Lau
Publikováno v:
Molecular Cancer Therapeutics. 8:A114-A114
Background: The oral PARP inhibitor olaparib (AZD2281, KU-0059436) has shown anti-tumor activity in patients with hereditary BRCA mutations and provides positive evidence for synthetic lethal approaches for the treatment of cancers with DNA repair de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f04961d26900b25ca83d90c65c61499
https://doi.org/10.1158/1535-7163.targ-09-a114
https://doi.org/10.1158/1535-7163.targ-09-a114
Autor:
Louise Unwin, Aisling O'Shaughnessy, Mark J. O'Connor, Darren Hodgson, John E. Prime, Ramu Mangena, Alan Lau, Sarah Runswick, Charlotte Knights, Jonathan R. Dry, Tim Avis, Lucy Riches, Simon Dearden, Chris Harbron, Helen Brown, James Carmichael
Publikováno v:
Molecular Cancer Therapeutics. 8:C119-C119
Background: The oral PARP inhibitor olaparib (AZD2281, KU-0059436) is in Phase II clinical trials in patients with BRCA-mutated breast and ovarian cancer. Early results in these trials have provided positive clinical evidence for the targeted therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42be693d293b7e09e8b6d7425f448541
https://doi.org/10.1158/1535-7163.targ-09-c119
https://doi.org/10.1158/1535-7163.targ-09-c119